NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

Bridging studies are not comparatively complicated or time consuming given the company already has rigorous assays in place which ensure 98% vaccine potency.

There's absolutely not a trial needed with Flaskworks. We only need to create a vaccine from patient using clean room process as well as Flaskworks then use assays with methods such as protemoics, like we saw at ASCO 2023, to ensure vaccines have equivalent composition!

That's it. We already know how to do these studies. In fact the firm are doing this all the time internally, I guarantee, to validate that Flaskworks actually works. Handing over our internal data, in the format of a government report, as well as having more inspections isn't anything complicated as we've already done this with our existing GMP facility in the MIA license process.